ACET Adicet Bio Inc

$ACET news coming here on Monday... one of those Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis "today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis on Monday, September 28, 2026."

$ACET Huge upside... The stock is going to fly very soon. Right time to get in . Positive clincal trail. But the prices have fallen. This will bounce in no time... 🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥

$ACET price target raised by Wedbush and HC Wainwright, meanwhile stock goes down, need more price target raised

$ACET no red flags in HCW presentation. CEO discussed moving into pivotal LN study (maybe add SLE too) and startup activities beginning in q4 and final FDA protocol q4. Sounds like they think they have a win coming:

$ACET Probably better results than any of us expected and the stock is down in the premarket. Hopefully, the volume picks up after the webcast. Everything is red in the premarket.

$ACET great trial results! I added a bunch more this morning on this sell off. These are just biotech games to allow whales/institutions to load up . A $64 million market cap for this company is crazy low. They still have to deal with financing at some point but for this low a market cap big pharma could just come in and buy them at what amounts to a rounding error in a quarterly report for them.

$ACET All efficacy evaluable patients (22 of 22) achieved undetectable CD19+ B cells, followed by naïve-dominant B-cell reconstitution.

$ACET One month ago it was $10 a share. Now with a positive clinical trial where should it be. Grossly misunderstood. This will fly in no matter of time. 🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥fly

$ACET shows promising Phase 1 data for prula-cel in lupus, with high remission rates and favorable safety.

BIOTECH CATALYST WATCH — SEPT. 28 $ACET — Phase 1 prula cel lupus clinical data. Webcast 8:00 AM ET. $MIRM — Phase 3 AZURE 1 topline results for brelovitug. 8:30 AM ET. $KOD — Phase 3 DAYBREAK topline results for Zenkuda + KSI 501. Webcast 8:30 AM ET. Three major clinical readouts on deck this morning. Watching for the headlines + volume reaction.

$ACET all car-t are struggling look at $CRBU it’s done now with discontinuation of its internal CAR-T programs, even other companies are scrapping some of their programs or pivoting like $CLLS , even $CAPR it started a bearish trend.

$ACET The company has been severely lagging on timely execution, and it is becoming increasingly clear that its regulatory preparations were not sufficiently advanced. Yesterday’s guidance on regulatory interactions was disappointing, suggesting that Q1’27 may be a reasonable timeframe to see FDA meeting minutes confirming the registrational trial details. By then, the company would have only around six months of cash remaining. The RMAT designation should have been secured much earlier and could have helped accelerate the overall development pace. While yesterday’s clinical update exceeded my expectations, the painfully slow execution is increasingly putting the company at risk.

$ACET Sometimes the market does no read the news and the data, especially as algorithm driven trading cannot understand the nuances. Here the nuance is that the ORR is achieved for 21/22 patients "steroids free", which makes the comparison with other treatments a-symmetric. We shall see whether with a few more days to read and understand, the market corrects its initial view.

$ACET for anyone interested, the investor presentation on the Adicet website entitled Prula-cel Clinical Data Update on 9/28 gives a very good overview of where the company is and what advantages their product has over the competition.

$ACET “At the 12-month mark, 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) and 54% of evaluable patients achieved DORIS remission. All 12-month responses were ongoing at 12 to 21 months of follow-up, except 1 patient with UPCR 0.65 g/g who remains off immunosuppressants.“

$ACET Between this and KOD........ Which one will it be? KOD looks like its going to rip in premarket on Monday.......may not have to wait for the news

$ACET 2 weeks of gain wiped out in 2 hours. They better have a solid story during HCW Conference today

$ACET Balance Sheet Total Cash (mrq) 118.19M Total Cash Per Share (mrq) 10.98 Total Debt (mrq) 12.85M Total Debt/Equity (mrq) 10.70% Current Ratio (mrq) 6.71 Book Value Per Share (mrq) 11.16

$ACET oh you think this is your worst day as a shareholder? Better be brave. The sell off just starts…pink sheet listing incoming.

$ACET I'd say often enough when some turd biotech announces on a Friday in AH that they will publish results of a trial on monday a.m. there is a fake out in AH on Friday and the stock will be down on Monday a.m.